Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque

CONCLUSIONS: The use of PCSK9 inhibitors is accompanied by a beneficial remodelling of the inflammatory burden within the human atheroma, an effect possibly or partly independent of their LDL-C lowering ability. This phenomenon might provide an additional cardiovascular benefit.PMID:37422356 | DOI:10.1016/j.atherosclerosis.2023.06.971

Source: Atherosclerosis - July 8, 2023 Category: Cardiology Authors: Raffaele Marfella Francesco Prattichizzo Celestino Sardu Pasquale Paolisso Nunzia D'Onofrio Lucia Scisciola Rosalba La Grotta Chiara Frig é Franca Ferraraccio Iacopo Panarese Mara Fanelli Piero Modugno Antonio Maria Calafiore Mario Melchionna Ferdinando Source Type: research